Eupraxia Pharmaceuticals (EPRX) Earnings Date, Estimates & Call Transcripts $3.20 -0.07 (-2.14%) As of 01:03 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Eupraxia Pharmaceuticals Latest Earnings SummaryUpcoming Q1 Earnings DateApr. 7EstimatedActual EPS (Mar. 20) -$0.21 Missed By -$0.01 Consensus EPS (Mar. 20) -$0.20 Eupraxia Pharmaceuticals announced Q4 2024 earnings on March 20, 2025, reporting an EPS of -$0.21, which missed the consensus estimate of -$0.20 by $0.01. With a trailing EPS of -$0.76, Eupraxia Pharmaceuticals' earnings are expected to grow next year, from ($0.67) to ($0.60) per share. EPRX Upcoming EarningsEupraxia Pharmaceuticals' next earnings date is estimated for Monday, April 7, 2025, based off prior year's reporting schedules. Get Eupraxia Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataEPRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.EPRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Eupraxia Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($0.67) EPSNext Year EPS Consensus Estimate: ($0.60) EPS Remove Ads Eupraxia Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 4/7/2025(Estimated)-------3/20/2025Q4 2024-$0.20-$0.21 -$0.01-$0.21--11/7/2024---$0.17 -$0.17-$0.17--8/7/2024Q2 2024--$0.17 -$0.17-$0.17--5/8/2024Q1 2024--$0.21 -$0.21-$0.21--4/1/2024Q4 2023--$0.17 -$0.17-$0.17--11/14/2023Q3 2023--$0.26 -$0.26-$0.26--8/11/2023Q2 2023--$0.36 -$0.36-$0.36--5/11/2023Q1 2023--$0.23 -$0.23-$0.23-- Eupraxia Pharmaceuticals Earnings - Frequently Asked Questions When is Eupraxia Pharmaceuticals's earnings date? Eupraxia Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, April 7th, 2025 based off last year's report dates. Learn more on EPRX's earnings history. Did Eupraxia Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Eupraxia Pharmaceuticals (NASDAQ:EPRX) missed the analysts' consensus estimate of ($0.20) by $0.01 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. EPRX's actual earnings. How much profit does Eupraxia Pharmaceuticals generate each year? Eupraxia Pharmaceuticals (NASDAQ:EPRX) has a recorded net income of -$28.22 million. EPRX has generated -$0.76 earnings per share over the last four quarters. What is Eupraxia Pharmaceuticals's EPS forecast for next year? Eupraxia Pharmaceuticals's earnings are expected to grow from ($0.67) per share to ($0.60) per share in the next year. More Earnings Resources from MarketBeat Related Companies Tyra Biosciences Earnings Results Akebia Therapeutics Earnings Results Sionna Therapeutics Earnings Results Cullinan Therapeutics Earnings Results Maze Therapeutics Earnings Results Precigen Earnings Results Mind Medicine (MindMed) Earnings Results Relay Therapeutics Earnings Results Zevra Therapeutics Earnings Results SIGA Technologies Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Remove Ads This page (NASDAQ:EPRX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
